Scalper1 News
Specialty-drug giant Valeant Pharmaceuticals (VRX) is set to report Q3 earnings Monday before the open, but the company’s emerging role as chief villain to drug-price critics is already overshadowing the report. On Wednesday, Valeant said that it had received subpoenas from district attorneys in Massachusetts and New York after members of both the House and Senate advocated looking into the enormous price increases that the company has given some Scalper1 News
Scalper1 News